Genfit SA
Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fi… Read more
Genfit SA (GNFTF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: -0.574x
Based on the latest financial reports, Genfit SA (GNFTF) has a cash flow conversion efficiency ratio of -0.574x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-30.10 Million) by net assets ($52.47 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Genfit SA - Cash Flow Conversion Efficiency Trend (2004–2024)
This chart illustrates how Genfit SA's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Genfit SA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Genfit SA ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
United States Cellular Corporation
NYSE:USM
|
-0.100x |
|
Sylvania Platinum Limited
OTCGREY:SAPLF
|
0.052x |
|
Zhejiang Changhua Auto Parts Co Ltd
SHG:605018
|
0.048x |
|
Zhejiang Haisen Pharmaceutical Co. Ltd. A
SHE:001367
|
N/A |
|
Jmicron Technology
TWO:4925
|
0.005x |
|
Asia Cuanon Tech (Shanghai)
SHG:603378
|
0.099x |
|
Fundamental Global Inc.
NASDAQ:FGNXP
|
-0.003x |
|
DR Corporation Limited
SHE:301177
|
N/A |
Annual Cash Flow Conversion Efficiency for Genfit SA (2004–2024)
The table below shows the annual cash flow conversion efficiency of Genfit SA from 2004 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $69.22 Million | $15.55 Million | 0.225x | +127.54% |
| 2023-12-31 | $67.95 Million | $-55.43 Million | -0.816x | -6.15% |
| 2022-12-31 | $94.53 Million | $-72.64 Million | -0.768x | -191.60% |
| 2021-12-31 | $119.10 Million | $99.92 Million | 0.839x | -85.93% |
| 2020-12-31 | $-16.16 Million | $-96.37 Million | 5.963x | +1151.31% |
| 2019-12-31 | $84.06 Million | $-47.68 Million | -0.567x | +78.82% |
| 2018-12-31 | $20.94 Million | $-56.08 Million | -2.678x | -459.93% |
| 2017-12-31 | $104.23 Million | $-49.86 Million | -0.478x | -150.88% |
| 2016-12-31 | $142.80 Million | $-27.23 Million | -0.191x | +28.95% |
| 2015-12-31 | $55.42 Million | $-14.87 Million | -0.268x | -21.99% |
| 2014-12-31 | $70.43 Million | $-15.49 Million | -0.220x | +66.27% |
| 2013-12-31 | $14.09 Million | $-9.19 Million | -0.652x | +43.31% |
| 2012-12-31 | $6.83 Million | $-7.86 Million | -1.150x | +27.92% |
| 2011-12-31 | $4.46 Million | $-7.11 Million | -1.596x | -148.23% |
| 2010-12-31 | $8.39 Million | $-5.39 Million | -0.643x | -4415.44% |
| 2009-12-31 | $15.52 Million | $-221.00K | -0.014x | +93.83% |
| 2008-12-31 | $22.38 Million | $-5.16 Million | -0.231x | -21.55% |
| 2007-12-31 | $25.37 Million | $-4.81 Million | -0.190x | -202.28% |
| 2006-12-31 | $27.77 Million | $-1.74 Million | -0.063x | -150.16% |
| 2005-12-31 | $13.39 Million | $1.68 Million | 0.125x | -54.99% |
| 2004-12-31 | $14.00 Million | $3.89 Million | 0.278x | -- |